TrialPath
Recruiting

SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition

NCT07530757 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Randomized Controlled Trial to Assess the Efficacy of a Supervised Computerized Active Program (SuperCAP) to Improve Cognition and Daily Functioning in People With Post-COVID-19 Condition
About this study
-COVID-19 Condition (PCC) is a major public health challenge, with cognitive impairment and fatigue among its most prevalent and disabling symptoms, leading to substantial limitations in quality of life and daily functioning. Digital health solutions provide an opportunity to expand access to structured, evidence-informed care. SuperCAP was developed as a multidisciplinary digital therapeutic program to support cognitive and functional recovery in individuals with PCC. A randomized pilot study demonstrated its feasibility and acceptability, supporting the conduct of a larger randomized controlled trial to evaluate its efficacy on disability and cognitive outcomes. Participants will be randomized (1:1) to receive the digital intervention (SuperCAP) or Standard of Care (SoC) during 13 weeks, followed by a 12-week observation period. The primary objective is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment. The secondary objectives include evaluating the effects of SuperCAP on quality of life, daily functioning, cognitive and emotional outcomes, the durability of these effects at follow-up, and the feasibility and acceptability of program implementation.
Eligibility criteria
Inclusion Criteria: * Diagnosis of PCC, defined as the presence of three or more symptoms associated with COVID-19 infection for at least three months, not explained by other diseases. * Age 18 to 65 years. * Willingness to participate in an app-based intervention program aimed at improving daily Functioning in People Living with PCC. * Evidence of patient-reported cognitive difficulties emerging after COVID-19, operationalized as a WHODAS 2.0 Cognition Domain (D1) score \> 6 at baseline via RedCAP. * Digital proficiency defined as scoring ≥4 on MDPQ-16 item 2a (sending emails) and ≥3 on item 6a (using the device's app store) via RedCAP. * Self-reported ability to use a mobile application for approximately 15 minutes per day, 5 days per week, considering their current symptoms. * Possession of a personal smartphone compatible with the study mobile application (eSalut), with sufficient storage space and operating system version required for installation. Exclusion Criteria: * Inability to undergo neuropsychological tests or additional assessments. * Prior use of the SuperCAP program. * Current participation in a trial or program aimed at improving PCC symptoms. * Any condition that, in the investigator's opinion, could make participation unsafe, complicate interpretation of study results, interfere with achievement of study objectives, or otherwise affect the participant's ability to complete the study.
Study design
Enrollment target: 100 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-07-15
Estimated completion: 2027-04
Last updated: 2026-09-11
Interventions
Device: SuperCAP intervention programOther: Psychoeducational intervention
Primary outcomes
  • To determine whether the SuperCAP intervention program is superior to control in reducing disability. (From baseline (week 0) to the post-intervention assessment (week 13).)
Sponsor
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · other
With: Fundació Institut Germans Trias i Pujol
Contacts & investigators
ContactAnna Prats, PhD · contact · aprats@lluita.org · +34934657897
ContactDavid Rovira · contact · drovira@scienhub.org · +34934978849
InvestigatorAnna Prats, PhD · principal_investigator, Fundació Lluita contra les Infeccions
All locations (1)
Fundació Lluita contra les Infeccions - Hospital Universitari Germans Trias i PujolRecruiting
Badalona, Barcelona, Spain
SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition · TrialPath